Joachim Drevs

Joachim Drevs

UNVERIFIED PROFILE

Are you Joachim Drevs?   Register this Author

Register author
Joachim Drevs

Joachim Drevs

Publications by authors named "Joachim Drevs"

Are you Joachim Drevs?   Register this Author

41Publications

-Reads

First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors.

J Clin Oncol 2014 Dec 17;32(36):4141-8. Epub 2014 Nov 17.

Beate Schultheis and Dirk Strumberg, Marienhospital Herne/University of Bochum, Herne; Ansgar Santel, Christiane Vank, Frank Gebhardt, Oliver Keil, Christian Lange, Klaus Giese, Jörg Kaufmann, and Michael Khan, Silence Therapeutics, Berlin; and Joachim Drevs, UniFontis Clinic, Tübingen, Germany.

View Article
December 2014

Biomarkers in tumor angiogenesis and anti-angiogenic therapy.

Int J Mol Sci 2011 21;12(10):7077-99. Epub 2011 Oct 21.

Hematology and Oncology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria; E-Mails: (A.P.); (W.H.).

View Article
November 2014

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.

Invest New Drugs 2012 Oct 12;30(5):1962-71. Epub 2011 Oct 12.

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisbug-Essen Essen, Hufelandstr. 55, 45122, Essen, Germany.

View Article
October 2012

Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors.

Int J Clin Pharmacol Ther 2012 Jan;50(1):76-8

Department of Hematology and Oncology, Marienhospital Herne, University of Bochum, Herne, Germany.

View Article
January 2012

Liver cancer: Targeted future options.

World J Hepatol 2011 Feb;3(2):38-44

Andreas Pircher, Department for Hematology and Oncology, Medical University Innsbruck, Anichstr. 35, Innsbruck 6020, Austria.

View Article
February 2011

Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.

Anticancer Res 2009 Dec;29(12):5065-76

Department of Medical Oncology, Tumor Biology Center at the Albert Ludwigs University, Freiburg, Germany.

View Article
December 2009

AMT: preclinical pharmacology studies.

Int J Oncol 2009 May;34(5):1341-52

Auron Healthcare GmbH, 79100 Freiburg, Germany.

View Article
May 2009

Mode of action and clinical impact of VEGF signaling inhibitors.

Expert Rev Anticancer Ther 2009 May;9(5):649-62

Cancer Hospital SanaFontis, An den Heilquellen 2, 79111 Freiburg, Germany.

View Article
May 2009

Molecular targeted therapies for solid tumors: management of side effects.

Onkologie 2009 Mar 16;32(3):129-38. Epub 2009 Feb 16.

Klinik für Hamatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Germany.

View Article
March 2009

Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.

Onkologie 2007 Dec 30;30(12):629-35. Epub 2007 Nov 30.

Tumor Biology Center at the Albert Ludwigs University Freiburg and MR Development and Application Center of the University Hospital, Freiburg, Germany.

View Article
December 2007

Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.

Clin Cancer Res 2007 Aug;13(16):4858-66

Department Medical Oncology, Tumor Biology Center, Freiburg, Germany.

View Article
August 2007

Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice.

Graefes Arch Clin Exp Ophthalmol 2005 Jun 14;243(6):593-600. Epub 2005 Jan 14.

Department of Ophthalmology, University of Freiburg, Killianstr. 5, 79106, Freiburg, Germany.

View Article
June 2005

Receptor tyrosine kinases and anticancer therapy.

Curr Pharm Des 2005 ;11(9):1139-49

Tumor Biology Center, Breisacherstr. 117, 79106 Freiburg, Germany.

View Article
May 2005

Plasma vascular endothelial growth factor and serum soluble angiopoietin receptor sTIE-2 in patients with dural arteriovenous fistulas: a pilot study.

Neuroradiology 2005 Jan 14;47(1):10-7. Epub 2005 Jan 14.

Department of Neuroradiology, University of Freiburg, Breisacher Strasse 64, 79106 Freiburg, Germany.

View Article
January 2005

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.

Cancer Chemother Pharmacol 2004 Dec 21;54(6):514-24. Epub 2004 Aug 21.

Tumor Biology Center, Albert-Ludwigs University Freiburg, 79106, Freiburg im Breisgau, Germany.

View Article
December 2004

Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.

Anticancer Res 2004 May-Jun;24(3a):1759-63

Department of Medical Oncology, Tumor Biology Center, Freiburg, Germany.

View Article
September 2004

Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma.

Anticancer Res 2003 Nov-Dec;23(6C):4853-8

Department of Medical Oncology, Tumor Biology Center, Breisacher Strasse 117, D-79106 Freiburg, Federal Republic of Germany.

View Article
April 2004

ZD-6126 AstraZeneca.

IDrugs 2004 Apr;7(4):380-7

Tumor Biology Center, Department of Medical Oncology, Breisacher Strasse 117, 79106 Freiburg, Germany.

View Article
April 2004

[Receptor tyrosine kinases. A target for new cancer treatments].

Med Monatsschr Pharm 2004 Feb;27(2):50-8; quiz 59-60

Klinik für Internistische Onkologie, Freiburg, Germany.

View Article
February 2004

[Bisphosphonates in oncology].

Med Monatsschr Pharm 2003 Dec;26(12):411-7

Klinik für Tumorbiologie Freiburg, Breisacherstr. 117, 79106 Freiburg.

View Article
December 2003

PTK/ZK (Novartis).

Authors:
Joachim Drevs

IDrugs 2003 Aug;6(8):787-94

Institute of Molecular Oncology, Department of Medical Oncology, Tumor Biology Center, Breisacher Strasse 117, 79106 Freiburg, Germany.

View Article
August 2003

Soluble markers for the detection of hypoxia under antiangiogenic treatment.

Authors:
Joachim Drevs

Anticancer Res 2003 Mar-Apr;23(2A):1159-61

Tumor Biology Center, Albert-Ludwigs-University Hospital, Breisacherstr. 117, D-79106 Freiburg, Germany.

View Article
July 2003

Receptor tyrosine kinases: the main targets for new anticancer therapy.

Curr Drug Targets 2003 Feb;4(2):113-21

Tumor Biology Center, Breisacherstr. 117, 79106 Freiburg, Germany.

View Article
February 2003

Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma.

Head Neck 2002 Aug;24(8):773-8

Department of Otolaryngology-Head and Neck Surgery, Hull Royal Infirmary, Hull, United Kingdom.

View Article
August 2002